Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A family voice and a glimpse of home: a new weapon against ICU delirium?

NCT ID NCT07776002

Prevention Sponsor: Taipei Veterans General Hospital, Taiwan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial tests whether a short, personalized audiovisual program—featuring a family member's voice, current date and weather, and images of the hospital's surroundings—can prevent delirium and reduce agitation and pain in adults aged 55 and older in an emergency intensive care unit. Participants receive the 2-minute session three times daily for two days, starting within 24 hours of admission. Researchers will compare their outcomes with those receiving routine care alone, measuring delirium, agitation, and pain over the two-day period.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A personalized audiovisual intervention featuring a family member's message, date and weather updates, and local images, delivered for 2 minutes three times daily.
What this could lead to
If effective, this simple, non-drug approach could offer a new way to prevent delirium and reduce agitation and pain in older intensive care patients.
What could go wrong
This is a small, non-randomized study, so results may not apply broadly. The intervention is brief and may not overcome the many factors that trigger delirium in critical illness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 128 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 55 years or older. 2. Admitted to the emergency intensive care unit within the previous 24 hours. 3. No delirium at baseline, defined as a negative Confusion Assessment Method for the Intensive Care Unit assessment and a CAM-ICU-7 score of 0-2. 4. Acute Physiology and Chronic Health Evaluation II (APACHE II) score ≥14. 5. Sufficiently alert to communicate, with a Glasgow Coma Scale score of E4V4-5M6 or E4VTM6. 6. Diagnosed with an infection or an infection-related critical illness, such as sepsis, urinary tract infection, or pneumonia. Exclusion Criteria: 1. Diagnosed visual or hearing impairment that would interfere with receiving the audiovisual intervention. 2. History of substance abuse. 3. History of psychiatric illness. 4. Moribund status, receipt of a palliative care consultation, or an expected survival of 7 days or less. 5. Unable to communicate in Mandarin Chinese or Taiwanese Hokkien. 6. No family caregiver available to participate in preparation of the audiovisual intervention. 7. History of surgery within the previous 7 days. 8. Montreal Cognitive Assessment (MoCA) score \<23.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Delirium confusional state are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Confusion delirium prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Delirium confusional state

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.